Positive effect of reltecimod on resolution of organ dysfunction in phase III ACCUTE trial for patients with necrotizing soft tissue infection .- Atox Bio
Atox Bio announced results from the randomized, double-blind, placebo-controlled Phase III ACCUTE (AB103 Clinical Composite endpoint StUdy in Necrotizing Soft Tissue infEctions) trial of reltecimod for the early… read more.